Spirit Realty Capital, Inc. (SRC) saw its value decrease by -0.28% as the stock dropped $-0.03 to finish the day at a closing price of $10.68. The stock was higher in trading and has fluctuated between $10.2-$13.97 per share for the past year. The shares, which traded within a range of $10.51 to $10.73 during the day, are up by 2.2% in the past three months and down by -16.3% over the past six months. It is currently trading -0.08% below its 20 day moving average and -0.08% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $12.62 a share over the next twelve months. The current relative strength index (RSI) reading is 51.18.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Spirit Realty Capital, Inc. is a publicly traded real estate investment trust. The firm primarily acquires across the United States single tenant operationally essential real estate, which refers to generally free-standing, commercial real estate facilities where tenants conduct retail, service or distribution activities that are essential to the generation of their sales and profits. The firm was formerly known as Spirit Finance Corp. Spirit Realty Capital, Inc. was formed on August 14, 2003 and is domiciled in the United States.
The Western Union Company (WU) shares were down in last trading by -0.46% to $19.59. It experienced lighter than average volume on day. The stock decreased in value by almost -1.61% over the past week and fell -11% in the past month. It is currently trading -7.23% below its 50 day moving average and -2.75% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -13.7% decrease in value from its one year high of $22.7. The RSI indicator value of 36.9, lead us to believe that it is a hold for now.
The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers money transfer services. This segment provides various options for sending funds, including walk-in and online money transfer, as well as account based money transfer services through a network of third-party agents using multi-currency and real-time money transfer processing systems. The Consumer-to-Business segment offers options to make one-time or recurring payments from consumers to businesses and other organizations, including utilities, auto finance companies, mortgage servicers, financial service providers, government agencies, and other businesses. It also provides various products, which provide consumers choices as to the payment channel and method of payment, including Speedpay, Pago Fácil, and Western Union Payments. This segment offers its services primarily through the phone and Online, as well as through its agent networks and selected company-owned locations. The Business Solutions segment facilitates payment and foreign exchange solutions, primarily cross-border and cross-currency transactions for small and medium size enterprises and other organizations, as well as for individuals. This segment provides its services through the phone, partner channels, and the Internet. As of December 31, 2015, the company had a network of approximately 500,000 agent locations in approximately 200 countries and territories. The Western Union Company was incorporated in 2006 and is headquartered in Englewood, Colorado.
Exelixis, Inc. (EXEL) traded within a range of $21.58 to $22.13 after opening the day at $22. The company has seen its stock increase in value by 48.22% so far this year. The stock was up close to 0.36% on light volume in last trading session and closed at $22.1 per share. After the recent gain, the stock is currently holding -4% below its 52 week high of $23.02 and 522.54% above its 12-month low of $3.55. The shares are up by over 31.86% in the last three months, and the RSI indicator value of 68.39 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.